[Federal Register Volume 67, Number 193 (Friday, October 4, 2002)]
[Notices]
[Page 62254]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-25231]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting: Scientific Workshop--Menopausal Hormone Therapy

    Notice is hereby given that the Office of the Director, National 
Institutes of Health (NIH), Department of Health and Human Services, 
will convene a workshop on October 23, 2002, 8:30 am-5 pm; and October 
24, 2002, 8:30 am-3:30 pm. The workshop will be held at the Natcher 
Conference Center, NIH, 45 Center Drive, Bethesda, Maryland 20892.
    This meeting is open to the public. Advance registration and 
evidence of such upon arrival are required as seating is limited. 
Proceedings will be videocast to additional conference rooms within the 
Natcher Conference Center. The meeting will be webcast at http://videocast.nih.gov/. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.
    The purpose of this NIH conference is to review the results from 
the arm of the Women's Health Initiative (WHI) clinical trial studying 
the use of combination estrogen and progestin in post-menopausal women. 
This portion of the clinical trial was halted recently. The workshop 
will place the results of this portion of the trial in the context of 
other completed and ongoing Federally funded research on menopausal 
combination hormone therapy (HT). It will help clinicians and patients 
understand the implications of current knowledge on decisions regarding 
short- and long-term use of HT. In addition, the most recent 
information from the U.S. Preventive Services Task Force on hormone 
therapy and its use for chronic disease prevention will be presented, 
as will recommendations on specific clinical uses of HT from 
professional organizations. The conference will provide information 
about alternatives for HT for treatment of specific conditions such as 
osteoporosis, heart disease, and vasomotor symptoms that include mood 
and sleep disorders. Other ongoing studies will be reviewed.
    Time will be provided for public statements to be presented during 
the second day of the workshop, October 24. Any registered participant 
may submit a statement of no more than five double-spaced typewritten 
pages. All statements submitted will be made available as handouts 
during the conference. Due to time constraints, oral statements will be 
accommodated on a first-come first-served basis, and will be limited to 
three minutes each. Registration forms and requests to present oral 
statements should be sent to Ms. Robin Counts, Courtesy Associates 
Inc., 2025 M Street, NW, Suite 800, Washington, DC, 20036. To register 
for this conference, please use the online registration form at http://www4.od.nih.gov/orwh/ or contact the Courtesy Associates HT Conference 
Line at 202-973-8673 ([email protected]) by October 14, 2002.

    Dated: September 26, 2002.
Ruth L. Kirschstein,
Deputy Director, NIH.
[FR Doc. 02-25231 Filed 10-3-02; 8:45 am]
BILLING CODE 4140-01-P